Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
Clinical trial NCT02912572 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02912572
- Sponsor
- Dana-Farber Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-11-14
- Primary completion
- 2023-11-15
- Enrollment
- 106
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.